Hello Reader,
Here's what scope of practice confusion actually looks like in psychedelic work, and why both directions cause harm.
The over-referral version: a client mentions curiosity about psilocybin for depression. The clinician isn't sure what they're supposed to do with that, so they deflect. Maybe they suggest the client "find a specialist." Maybe they just redirect the session. The client gets the message: this isn't something you can bring here. The conversation ends. The clinician was probably well within their scope to have it. They just didn't know what the conversation was supposed to look like, and the client leaves carrying that silence.
The under-referral version: a client is actively using MDMA without therapeutic support. The clinician is aware of the use but doesn't probe further because they're unsure how to evaluate what they're seeing. They don't ask about cardiovascular risk. They don't ask what else the client is taking. They don't document. The therapeutic contact continues, but without the information the clinician needs to keep the client safe, and the client remains exposed.
Both failure modes come from the same place: inadequate training in what falls inside a licensed MH professional's scope when a client brings psychedelics into the room. It's not a knowledge gap about pharmacology. It's a framework gap about what to do.
The consequences aren't abstract. Clients in the over-referral scenario lose a therapeutic relationship for asking a question. Clients in the under-referral scenario have unscreened contraindications and no safety net, and both outcomes leave people less protected than they should be.
This is the problem the course addresses directly: what falls inside your scope, what falls outside it, and the clinical skills to act confidently in either situation.
Psychedelics and the Therapeutic Frame — 3 CEs, $137 →
— Peter